Left ventricular ejection fraction prior to and during follow-up after cardiac SBRT reported in the studies
| Number . | First author, year . | n . | Left ventricular ejection fraction (%) . | ||||
|---|---|---|---|---|---|---|---|
| . | . | Pre-SBRT . | Follow-up post-SBRT . | . | |||
| . | . | Median (range) . | Mean ± SD . | Median (range) . | Mean ± SD . | Mean difference . | |
| 1 | Cuculich P. 2017 | 5 | (15–37) | 23 ± 9 | (change −2 to +22) | 29 | +6 |
| 2 | Robinson C. 2019 | 19 | 25 (15–58) | 29 ± 12a | N/Ab | – | |
| 3 | Neuwirth R. 2019 | 10 | (20–35) | 27 ± 3 | No change | 27 ± 3c | +0 |
| 4 | Lloyd M. 2020 (Wight J.2022) | 10 (14) | N/A | N/A | – | ||
| 5 | Gianni C. 2020 | 5 | 25 (20–55) | 34 ± 15 | No change | 34 ± 15c | 0 |
| 6 | Ho L. 2021 | 7 | 43 (20–69) | 45 ± 18 | 42 (22–72) | 48 ± 20 | +3 |
| 7 | Yugo D. 2021 | 3 | (20–59) | 41 ± 20 | No change | 41 ± 20c | 0 |
| 8 | Chin R. 2021 | 8 | 20 (15–33) | 21 ± 7 | N/A | 27 ± 4 | +6 |
| 9 | Ho G. 2021 | 6 | 26 (10–46) | 29 ± 13 | N/A | – | |
| 10 | Carbucicchio C. 2021 | 7 | 21 (20–44) | 27 ± 11 | (n = 4) | 32 ± 5 | +5 |
| 11 | Lee J. 2021 | 7 | (15–45) | 27 ± 10 | No change (n = 5) | 27 ± 10c | 0 |
| 12 | Qian P. 2022 | 6 | 20 (IQR 16–20) | 18 ± 4a | 20 (IQR 13–20) | 17 ± 7a | 0 |
| 13 | Molon G. 2022 | 6 | (20–42) | 29 ± 9 | N/A | – | |
| 14 | Aras D. 2022 | 8 | 25 (10–30) | 24 ± 5 | N/A | – | |
| 15 | Ninni S. 2022 | 17 | 35 (20–53) | 34 ± 10 | N/A | 35 ± 11 | 0 |
| 16 | Chang W. 2022 | 5 | 32 (24–57) | 34 ± 12 | N/A | 39 ± 12 | +5 |
| 17 | van der Ree M. 2023 | 6 | 38 (24–52) | 38 ± 10 | N/A | 36 ± 6 | −2 |
| 18 | Amino M. 2023 | 3 | (20–65) | 37 ± 24 | N/A | – | |
| 19 | Krug D. 2023 | 5 | (20–45) | 35 ± 9 | (30–60) | 43 ± 11 | +8 |
| 20 | Herrera Siklody C. 2023 | 20 | 31 (20–72) | 37 ± 15 | N/A | – | |
| 21 | Miszczyk M. 2023 | 11 | 27 (20–40) | 28 ± 7 | 28 (15–57) | 32 ± 14 | +4 |
| 22 | Arkles J. 2024 | 14 | N/A | 32 ± 15 | N/A | 32 ± 12 | 0 |
| 23 | Hašková J. 2024 | 36 | N/A | 31 ± 10 | N/A | 31 ± 10 | 0 |
| Median (range) for studies | 26 (20–43) | 30 (18–45) | 26.5 (20–42) | 32 (17–48) | |||
| Patient summary | Weighted average | 30.9 ± 12.9 | 32.4 ± 13.1 | +1.5d | |||
| Number . | First author, year . | n . | Left ventricular ejection fraction (%) . | ||||
|---|---|---|---|---|---|---|---|
| . | . | Pre-SBRT . | Follow-up post-SBRT . | . | |||
| . | . | Median (range) . | Mean ± SD . | Median (range) . | Mean ± SD . | Mean difference . | |
| 1 | Cuculich P. 2017 | 5 | (15–37) | 23 ± 9 | (change −2 to +22) | 29 | +6 |
| 2 | Robinson C. 2019 | 19 | 25 (15–58) | 29 ± 12a | N/Ab | – | |
| 3 | Neuwirth R. 2019 | 10 | (20–35) | 27 ± 3 | No change | 27 ± 3c | +0 |
| 4 | Lloyd M. 2020 (Wight J.2022) | 10 (14) | N/A | N/A | – | ||
| 5 | Gianni C. 2020 | 5 | 25 (20–55) | 34 ± 15 | No change | 34 ± 15c | 0 |
| 6 | Ho L. 2021 | 7 | 43 (20–69) | 45 ± 18 | 42 (22–72) | 48 ± 20 | +3 |
| 7 | Yugo D. 2021 | 3 | (20–59) | 41 ± 20 | No change | 41 ± 20c | 0 |
| 8 | Chin R. 2021 | 8 | 20 (15–33) | 21 ± 7 | N/A | 27 ± 4 | +6 |
| 9 | Ho G. 2021 | 6 | 26 (10–46) | 29 ± 13 | N/A | – | |
| 10 | Carbucicchio C. 2021 | 7 | 21 (20–44) | 27 ± 11 | (n = 4) | 32 ± 5 | +5 |
| 11 | Lee J. 2021 | 7 | (15–45) | 27 ± 10 | No change (n = 5) | 27 ± 10c | 0 |
| 12 | Qian P. 2022 | 6 | 20 (IQR 16–20) | 18 ± 4a | 20 (IQR 13–20) | 17 ± 7a | 0 |
| 13 | Molon G. 2022 | 6 | (20–42) | 29 ± 9 | N/A | – | |
| 14 | Aras D. 2022 | 8 | 25 (10–30) | 24 ± 5 | N/A | – | |
| 15 | Ninni S. 2022 | 17 | 35 (20–53) | 34 ± 10 | N/A | 35 ± 11 | 0 |
| 16 | Chang W. 2022 | 5 | 32 (24–57) | 34 ± 12 | N/A | 39 ± 12 | +5 |
| 17 | van der Ree M. 2023 | 6 | 38 (24–52) | 38 ± 10 | N/A | 36 ± 6 | −2 |
| 18 | Amino M. 2023 | 3 | (20–65) | 37 ± 24 | N/A | – | |
| 19 | Krug D. 2023 | 5 | (20–45) | 35 ± 9 | (30–60) | 43 ± 11 | +8 |
| 20 | Herrera Siklody C. 2023 | 20 | 31 (20–72) | 37 ± 15 | N/A | – | |
| 21 | Miszczyk M. 2023 | 11 | 27 (20–40) | 28 ± 7 | 28 (15–57) | 32 ± 14 | +4 |
| 22 | Arkles J. 2024 | 14 | N/A | 32 ± 15 | N/A | 32 ± 12 | 0 |
| 23 | Hašková J. 2024 | 36 | N/A | 31 ± 10 | N/A | 31 ± 10 | 0 |
| Median (range) for studies | 26 (20–43) | 30 (18–45) | 26.5 (20–42) | 32 (17–48) | |||
| Patient summary | Weighted average | 30.9 ± 12.9 | 32.4 ± 13.1 | +1.5d | |||
aImputed.
bIn two patients LVEF improved by 13% and 8%.
cAssumed same as baseline based on reported as ‘no change’.
dP = 0.3 (independent sample t-test).
Left ventricular ejection fraction prior to and during follow-up after cardiac SBRT reported in the studies
| Number . | First author, year . | n . | Left ventricular ejection fraction (%) . | ||||
|---|---|---|---|---|---|---|---|
| . | . | Pre-SBRT . | Follow-up post-SBRT . | . | |||
| . | . | Median (range) . | Mean ± SD . | Median (range) . | Mean ± SD . | Mean difference . | |
| 1 | Cuculich P. 2017 | 5 | (15–37) | 23 ± 9 | (change −2 to +22) | 29 | +6 |
| 2 | Robinson C. 2019 | 19 | 25 (15–58) | 29 ± 12a | N/Ab | – | |
| 3 | Neuwirth R. 2019 | 10 | (20–35) | 27 ± 3 | No change | 27 ± 3c | +0 |
| 4 | Lloyd M. 2020 (Wight J.2022) | 10 (14) | N/A | N/A | – | ||
| 5 | Gianni C. 2020 | 5 | 25 (20–55) | 34 ± 15 | No change | 34 ± 15c | 0 |
| 6 | Ho L. 2021 | 7 | 43 (20–69) | 45 ± 18 | 42 (22–72) | 48 ± 20 | +3 |
| 7 | Yugo D. 2021 | 3 | (20–59) | 41 ± 20 | No change | 41 ± 20c | 0 |
| 8 | Chin R. 2021 | 8 | 20 (15–33) | 21 ± 7 | N/A | 27 ± 4 | +6 |
| 9 | Ho G. 2021 | 6 | 26 (10–46) | 29 ± 13 | N/A | – | |
| 10 | Carbucicchio C. 2021 | 7 | 21 (20–44) | 27 ± 11 | (n = 4) | 32 ± 5 | +5 |
| 11 | Lee J. 2021 | 7 | (15–45) | 27 ± 10 | No change (n = 5) | 27 ± 10c | 0 |
| 12 | Qian P. 2022 | 6 | 20 (IQR 16–20) | 18 ± 4a | 20 (IQR 13–20) | 17 ± 7a | 0 |
| 13 | Molon G. 2022 | 6 | (20–42) | 29 ± 9 | N/A | – | |
| 14 | Aras D. 2022 | 8 | 25 (10–30) | 24 ± 5 | N/A | – | |
| 15 | Ninni S. 2022 | 17 | 35 (20–53) | 34 ± 10 | N/A | 35 ± 11 | 0 |
| 16 | Chang W. 2022 | 5 | 32 (24–57) | 34 ± 12 | N/A | 39 ± 12 | +5 |
| 17 | van der Ree M. 2023 | 6 | 38 (24–52) | 38 ± 10 | N/A | 36 ± 6 | −2 |
| 18 | Amino M. 2023 | 3 | (20–65) | 37 ± 24 | N/A | – | |
| 19 | Krug D. 2023 | 5 | (20–45) | 35 ± 9 | (30–60) | 43 ± 11 | +8 |
| 20 | Herrera Siklody C. 2023 | 20 | 31 (20–72) | 37 ± 15 | N/A | – | |
| 21 | Miszczyk M. 2023 | 11 | 27 (20–40) | 28 ± 7 | 28 (15–57) | 32 ± 14 | +4 |
| 22 | Arkles J. 2024 | 14 | N/A | 32 ± 15 | N/A | 32 ± 12 | 0 |
| 23 | Hašková J. 2024 | 36 | N/A | 31 ± 10 | N/A | 31 ± 10 | 0 |
| Median (range) for studies | 26 (20–43) | 30 (18–45) | 26.5 (20–42) | 32 (17–48) | |||
| Patient summary | Weighted average | 30.9 ± 12.9 | 32.4 ± 13.1 | +1.5d | |||
| Number . | First author, year . | n . | Left ventricular ejection fraction (%) . | ||||
|---|---|---|---|---|---|---|---|
| . | . | Pre-SBRT . | Follow-up post-SBRT . | . | |||
| . | . | Median (range) . | Mean ± SD . | Median (range) . | Mean ± SD . | Mean difference . | |
| 1 | Cuculich P. 2017 | 5 | (15–37) | 23 ± 9 | (change −2 to +22) | 29 | +6 |
| 2 | Robinson C. 2019 | 19 | 25 (15–58) | 29 ± 12a | N/Ab | – | |
| 3 | Neuwirth R. 2019 | 10 | (20–35) | 27 ± 3 | No change | 27 ± 3c | +0 |
| 4 | Lloyd M. 2020 (Wight J.2022) | 10 (14) | N/A | N/A | – | ||
| 5 | Gianni C. 2020 | 5 | 25 (20–55) | 34 ± 15 | No change | 34 ± 15c | 0 |
| 6 | Ho L. 2021 | 7 | 43 (20–69) | 45 ± 18 | 42 (22–72) | 48 ± 20 | +3 |
| 7 | Yugo D. 2021 | 3 | (20–59) | 41 ± 20 | No change | 41 ± 20c | 0 |
| 8 | Chin R. 2021 | 8 | 20 (15–33) | 21 ± 7 | N/A | 27 ± 4 | +6 |
| 9 | Ho G. 2021 | 6 | 26 (10–46) | 29 ± 13 | N/A | – | |
| 10 | Carbucicchio C. 2021 | 7 | 21 (20–44) | 27 ± 11 | (n = 4) | 32 ± 5 | +5 |
| 11 | Lee J. 2021 | 7 | (15–45) | 27 ± 10 | No change (n = 5) | 27 ± 10c | 0 |
| 12 | Qian P. 2022 | 6 | 20 (IQR 16–20) | 18 ± 4a | 20 (IQR 13–20) | 17 ± 7a | 0 |
| 13 | Molon G. 2022 | 6 | (20–42) | 29 ± 9 | N/A | – | |
| 14 | Aras D. 2022 | 8 | 25 (10–30) | 24 ± 5 | N/A | – | |
| 15 | Ninni S. 2022 | 17 | 35 (20–53) | 34 ± 10 | N/A | 35 ± 11 | 0 |
| 16 | Chang W. 2022 | 5 | 32 (24–57) | 34 ± 12 | N/A | 39 ± 12 | +5 |
| 17 | van der Ree M. 2023 | 6 | 38 (24–52) | 38 ± 10 | N/A | 36 ± 6 | −2 |
| 18 | Amino M. 2023 | 3 | (20–65) | 37 ± 24 | N/A | – | |
| 19 | Krug D. 2023 | 5 | (20–45) | 35 ± 9 | (30–60) | 43 ± 11 | +8 |
| 20 | Herrera Siklody C. 2023 | 20 | 31 (20–72) | 37 ± 15 | N/A | – | |
| 21 | Miszczyk M. 2023 | 11 | 27 (20–40) | 28 ± 7 | 28 (15–57) | 32 ± 14 | +4 |
| 22 | Arkles J. 2024 | 14 | N/A | 32 ± 15 | N/A | 32 ± 12 | 0 |
| 23 | Hašková J. 2024 | 36 | N/A | 31 ± 10 | N/A | 31 ± 10 | 0 |
| Median (range) for studies | 26 (20–43) | 30 (18–45) | 26.5 (20–42) | 32 (17–48) | |||
| Patient summary | Weighted average | 30.9 ± 12.9 | 32.4 ± 13.1 | +1.5d | |||
aImputed.
bIn two patients LVEF improved by 13% and 8%.
cAssumed same as baseline based on reported as ‘no change’.
dP = 0.3 (independent sample t-test).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
